[FoRK] Making robotics a priority

J. Andrew Rogers andrew at ceruleansystems.com
Wed Jul 13 13:59:02 PDT 2011

On Jul 13, 2011, at 1:30 PM, Stephen Williams wrote:
> On 7/13/11 1:21 PM, Gregory Alan Bolcer wrote:
>> Article on innovation and competitiveness in today's WSJ.
>> http://online.wsj.com/article/SB10001424052702304447804576412084061290852.html?mod=WSJ_Opinion_LEADTop
>> Life-science companies today are among America's premier innovators. Six of the top 10 companies in global research and development expenditures are biopharmaceutical, according to a 2010 report by Booz & Co. American drug companies reinvest more than 20% of their U.S. sales revenues in research. As recently as 2008, more than 67% of all U.S. biopharmaceutical patents were issued to U.S.-based life-science companies.
> He should also have stated it as a % of gross profit.  After production, taxes, payroll, how much goes to reinvestment and how much is skimmed off as owner/investor profit?  Besides a bit of confusion between pay and profit, that would be interesting to know.

Average profit margins are 10-15% for that industry, which is pretty good.  

Since US companies produce around 70% of new pharma globally and a majority of that research is privately funded, they seem to be doing a pretty good job with whatever is they are doing with the money. 

More information about the FoRK mailing list